Exact Mass: 891.474182

Exact Mass Matches: 891.474182

Found 28 metabolites which its exact mass value is equals to given mass value 891.474182, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PG(a-15:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-3-[(12-methyltetradecanoyl)oxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C44H78NO13PS (891.4931227999999)


PG(a-15:0/LTE4) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(a-15:0/LTE4), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(LTE4/a-15:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-2-[(12-methyltetradecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C44H78NO13PS (891.4931227999999)


PG(LTE4/a-15:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(LTE4/a-15:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-15:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-3-[(13-methyltetradecanoyl)oxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C44H78NO13PS (891.4931227999999)


PG(i-15:0/LTE4) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-15:0/LTE4), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(LTE4/i-15:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-2-[(13-methyltetradecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C44H78NO13PS (891.4931227999999)


PG(LTE4/i-15:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(LTE4/i-15:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   

(4Z,7Z,10Z,13Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonan-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonan-2-yl]hexadeca-4,7,10,13-tetraenamide

C43H73NO18 (891.4827398)


   

(7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]hexadeca-7,10,13-trienamide

C43H73NO18 (891.4827398)


   

BiotinylPE(31:6)

BiotinylPE(9:0_22:6)

C46H74N3O10PS (891.4832274)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   

n-{1-[(1-{[1-({1-[(5-carbamimidamido-1-ethoxy-1-oxopentan-2-yl)-c-hydroxycarbonimidoyl]-2-(1h-indol-3-yl)ethyl}-c-hydroxycarbonimidoyl)-3-methylbutyl]-c-hydroxycarbonimidoyl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]-2-(4-hydroxyphenyl)ethyl}-7-methyloctanimidic acid

n-{1-[(1-{[1-({1-[(5-carbamimidamido-1-ethoxy-1-oxopentan-2-yl)-c-hydroxycarbonimidoyl]-2-(1h-indol-3-yl)ethyl}-c-hydroxycarbonimidoyl)-3-methylbutyl]-c-hydroxycarbonimidoyl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]-2-(4-hydroxyphenyl)ethyl}-7-methyloctanimidic acid

C46H69N9O9 (891.5217984)


   

n-[(1r)-1-{[(1s)-1-{[(1r)-1-{[(1s)-1-{[(2s)-5-carbamimidamido-1-ethoxy-1-oxopentan-2-yl]-c-hydroxycarbonimidoyl}-2-(1h-indol-3-yl)ethyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}-2-hydroxyethyl]-c-hydroxycarbonimidoyl}-2-(4-hydroxyphenyl)ethyl]-7-methyloctanimidic acid

n-[(1r)-1-{[(1s)-1-{[(1r)-1-{[(1s)-1-{[(2s)-5-carbamimidamido-1-ethoxy-1-oxopentan-2-yl]-c-hydroxycarbonimidoyl}-2-(1h-indol-3-yl)ethyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}-2-hydroxyethyl]-c-hydroxycarbonimidoyl}-2-(4-hydroxyphenyl)ethyl]-7-methyloctanimidic acid

C46H69N9O9 (891.5217984)


   

2-[(3r,6s,9r,12s,19r,23s,24as)-19-benzyl-1,4,7,10,17,23-hexahydroxy-12-[(4-hydroxyphenyl)methyl]-6-isopropyl-3-methyl-15-(6-methylheptyl)-13,20-dioxo-3h,6h,9h,12h,15h,16h,19h,22h,23h,24h,24ah-pyrrolo[2,1-o]1-oxa-4,7,10,13,16,19-hexaazacyclodocosan-9-yl]ethanimidic acid

2-[(3r,6s,9r,12s,19r,23s,24as)-19-benzyl-1,4,7,10,17,23-hexahydroxy-12-[(4-hydroxyphenyl)methyl]-6-isopropyl-3-methyl-15-(6-methylheptyl)-13,20-dioxo-3h,6h,9h,12h,15h,16h,19h,22h,23h,24h,24ah-pyrrolo[2,1-o]1-oxa-4,7,10,13,16,19-hexaazacyclodocosan-9-yl]ethanimidic acid

C46H65N7O11 (891.474182)


   

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(1h-imidazol-2-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}-10-methylundecanimidic acid

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(1h-imidazol-2-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}-10-methylundecanimidic acid

C40H65N11O12 (891.481393)


   

2-[(3r,6s,9r,12s,15s,19r,23r,24as)-19-benzyl-1,4,7,10,17,23-hexahydroxy-12-[(4-hydroxyphenyl)methyl]-6-isopropyl-3-methyl-15-(6-methylheptyl)-13,20-dioxo-3h,6h,9h,12h,15h,16h,19h,22h,23h,24h,24ah-pyrrolo[2,1-o]1-oxa-4,7,10,13,16,19-hexaazacyclodocosan-9-yl]ethanimidic acid

2-[(3r,6s,9r,12s,15s,19r,23r,24as)-19-benzyl-1,4,7,10,17,23-hexahydroxy-12-[(4-hydroxyphenyl)methyl]-6-isopropyl-3-methyl-15-(6-methylheptyl)-13,20-dioxo-3h,6h,9h,12h,15h,16h,19h,22h,23h,24h,24ah-pyrrolo[2,1-o]1-oxa-4,7,10,13,16,19-hexaazacyclodocosan-9-yl]ethanimidic acid

C46H65N7O11 (891.474182)


   

n-[(1s,2r)-2-hydroxy-1-[({[(1s)-1-{[(3s,6s,9s,12s)-5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl]dodecanimidic acid

n-[(1s,2r)-2-hydroxy-1-[({[(1s)-1-{[(3s,6s,9s,12s)-5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl]dodecanimidic acid

C40H65N11O12 (891.481393)


   

(2s)-2-[({3-benzyl-2,8,11,14-tetrahydroxy-4-methyl-6-[(methyl-c-hydroxycarbonimidoyl)methyl]-5-oxo-9-(2-phenylethyl)-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,7,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

(2s)-2-[({3-benzyl-2,8,11,14-tetrahydroxy-4-methyl-6-[(methyl-c-hydroxycarbonimidoyl)methyl]-5-oxo-9-(2-phenylethyl)-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,7,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

C44H65N11O9 (891.496648)


   

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}dodecanimidic acid

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}dodecanimidic acid

C40H65N11O12 (891.481393)


   

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}-10-methylundecanimidic acid

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}-10-methylundecanimidic acid

C40H65N11O12 (891.481393)


   

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(1h-imidazol-2-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}dodecanimidic acid

n-{2-hydroxy-1-[({[1-({5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(1h-imidazol-2-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl}dodecanimidic acid

C40H65N11O12 (891.481393)


   

n-[(1s,2r)-2-hydroxy-1-[({[(1s)-1-{[(3s,6s,9s,12s)-5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl]-10-methylundecanimidic acid

n-[(1s,2r)-2-hydroxy-1-[({[(1s)-1-{[(3s,6s,9s,12s)-5,8,11-trihydroxy-3,6-bis[2-(c-hydroxycarbonimidoyl)ethyl]-9-(3h-imidazol-4-ylmethyl)-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]propyl]-10-methylundecanimidic acid

C40H65N11O12 (891.481393)


   

(2s)-2-({[(3s,6s,9s,12r,15r)-3-benzyl-12-[(2s)-butan-2-yl]-2,5,11,14-tetrahydroxy-6-(c-hydroxycarbonimidoylmethyl)-7-methyl-8-oxo-9-(3-phenylpropyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

(2s)-2-({[(3s,6s,9s,12r,15r)-3-benzyl-12-[(2s)-butan-2-yl]-2,5,11,14-tetrahydroxy-6-(c-hydroxycarbonimidoylmethyl)-7-methyl-8-oxo-9-(3-phenylpropyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

C44H65N11O9 (891.496648)